Preventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program? by Scheen, André
Published in: Diabetes Care (2003), vol. 26, iss. 9, pp. 2701; author reply 2701-3 
Status: Postprint (Author’s version) 
Preventing, Delaying, or Masking Type 2 Diabetes With Metformin in the 
Diabetes Prevention Program? 
ANDRE J. SCHEEN, MD, PHD 
From the Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, Liège, Belgium. 
 
The secondary analysis of the Diabetes Prevention Program (DPP) showed that withdrawal of metformin for 1-2 
weeks resulted in a trend to a higher conversion rate from impaired glucose tolerance to diabetes as compared 
with the placebo group (1). This resulted in a reduction by 26% of the so-called prevention effect of metformin, 
i.e., from 31% in the primary analysis (2) to 25% in the secondary analysis, a reduction in the incidence of 
diabetes that, however, remained highly significant as compared with placebo. The same trend was observed in 
the Study to Prevent (STOP)-NIDDM trial with acarbose after a longer washout period of 3 months (3). As 
previously discussed (4) and emphasized in a previous Diabetes Care Editorial (5), one key question is to know 
whether the positive results with metformin in the DPP (2) or with acarbose in the STOP-NIDDM trial (3) could 
be interpreted as a real prevention of the disease or only as a delay in its progression, or even simply as a 
masking effect due to the metabolic effect of the drug. It was astonishing that a possible direct effect of 
metformin was not discussed in the original paper of the DPP, despite the fact that the results were initially 
presented without any washout period (2). Indeed, a significant improvement of insulin sensitivity and glucose 
metabolism was consistently demonstrated in placebo-controlled randomized clinical trials after only 48 h 
treatment with metformin (850 mg twice daily), both in insulin-resistant normoglycemic first-degree relatives of 
diabetic patients during a euglycemic insulin clamp (6) and in hyperglycemic patients with type 2 diabetes with 
the isotope dilution technique to measure hepatic glucose production (7). 
Using the frequently sampled intravenous glucose tolerance test and the minimal model approach, we also 
reported such acute favorable effect of metformin in a population similar to that of the DPP, i.e., in subjects with 
impaired glucose tolerance with a significant increase of the insulin sensitivity index after only 48 h metformin 
therapy (+50%; P = 0.03) (8). That part of the overall effect seen in the DPP may be accounted for by a pure 
pharmacological effect of metformin that did not persist when the drug was stopped (1) is in agreement with 
those experimental results (6-8). Furthermore, the rather short washout period of only 1-2 weeks may be 
questionable. First, it did not allow a sufficiently high number of new cases of diabetes, which limited the 
statistical power of the analysis (5)— the P value was 0.098 despite a difference of 49% in diabetes rates 
between placebo and metformin groups during the washout period. In addition, while the washout period was 
beyond the classically requested period of five times the plasma half-life of the drug (9), it did not completely 
exclude the persistence of any biological effect of metformin, which has a particularly complex cellular 
mechanism of action. Thus, in our opinion and in agreement with Buchanan (5), the question remains open as to 
whether the results of the DPP with metformin correspond to preventing, delaying, or partially masking effects 
of type 2 diabetes. 
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I agree with the fundamental point made by Dr. Scheen (1) in this issue of Diabetes Care. It is unclear whether 
the effect of metformin to reduce the incidence of diabetes during the Diabetes Prevention Program (DPP) (2) 
was true prevention or simply a masking of diabetes. The posttrial washout period was very short for testing that 
distinction. The data cited by Dr. Scheen regarding a very rapid effect of metformin to increase insulin 
sensitivity suggests that dissipation of any such effect in the DPP could have been rapid as well. Thus, acute 
effects of metformin on insulin sensitivity could have been gone 2 weeks after the drug was stopped. It seems 
unlikely that we will ever know for sure because direct measures of insulin sensitivity were not made in the DPP. 
Additionally, we will never know whether glucose levels had stabilized or were still rising 2 weeks after 
metformin was stopped. The Study to Prevent (STOP)-NIDDM trial (3) included a more convincing washout 
period of 3 months before retesting for diabetes. During the washout, the jump in new cases of diabetes in the 
former acarbose group (twice as many as in the former placebo group) was even more striking than the 
analogous jump in the former metformin group in the DPP (49% more cases than in the placebo group). Whether 
this greater jump in the STOP-NIDDM trial reflects the more meaningful washout period used in that trial or a 
greater component of masking rather than prevention of diabetes compared with metformin can't be determined 
from the published data. 
We have provided strong evidence from the Troglitazone in the Prevention of Diabetes (TRIPOD) study (4), 
conducted in Hispanic-American women, that lowering endogenous insulin requirements can slow or stop the 
loss of β-cell function, which leads to type 2 diabetes. If this effect occurs in other ethnic groups (still a big "if"), 
then any effect of metformin or acarbose to lower glucose levels or enhance insulin sensitivity could have had an 
analogous, albeit probably weaker, effect in the DPP and STOP-NIDDM trials. Given the known effects of 
metformin and acarbose on carbohydrate metabolism, I suspect that portions of the reductions in diabetes rates 
observed in the metformin arm of the DPP and in the STOP-NIDDM trial were due to β-cell protection. The 
posttrial washouts in the two studies demonstrate that some of the apparent protection from diabetes was simply 
masking caused by acute glucose-lowering effects of the drugs. 
We will never know precisely how much prevention and how much masking of diabetes occurred in the DPP 
and the STOP-NIDDM trials. Nonetheless, discourse on this issue can be helpful. It can focus diabetes 
prevention research on the real disease of type 2 diabetes— progressive β-cell failure—rather than on the 
glucose thresholds that currently define diabetes. Those thresholds are clearly important for assessing the risk of 
microvascular and neuropathic complications of diabetes. However, they are not very useful for tracking the 
underlying β-cell disease. That disease progresses for a long time before patients cross the glucose threshold to 
diabetes, and it continues after they have crossed that threshold. When the discussion turns to prevention (or 
even to initial treatment) of type 2 diabetes, the goal should become stability of glucose levels and β-cell 
function. 
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We appreciate the comments of Drs. Scheen (1) and Buchanan (2) regarding our article (3), which described the 
effects of withdrawal of metformin on diabetes status in the Diabetes Prevention Program (DPP). As Dr. Scheen 
comments, and as we pointed out in our article, clearly part of the effect of metformin was due to an acute 
pharmacological effect of metformin, but the great majority of the effect persisted beyond this period of washout. 
As he notes, the washout period of 1-2 weeks was indeed beyond the usual required period of five times the 
plasma half-life of the drug. The duration and nature of metformin's effects beyond that time frame are not well 
established. However, there are no data to support Dr. Scheen's conjecture that waiting for an additional time 
would "allow a sufficiently high number of new cases of diabetes," which he feels limited the statistical power of 
the analyses. The data are what they are. Within the DPP, the investigators felt that it would not be ethical to 
withhold such an efficacious treatment for a prolonged period of time to answer these questions. Furthermore, 
pharmacological treatment of many other chronic diseases, such as hypertension and dyslipidemia, is generally 
given continuously. We don't expect drugs treating these conditions to work after they are discontinued. 
Similarly, we shouldn't expect drug treatment of impaired glucose regulation and other risk factors for type 2 
diabetes to be effective after the drugs are discontinued. 
We agree that whether drug therapy with metformin, acarbose, troglitazone, estrogens, ACE inhibitors, or 
angiotensin II receptor blockers truly prevent diabetes or delay its onset cannot be determined completely by the 
existing studies. However, delaying the onset of diabetes is clearly an important goal with major individual and 
public health implications. From a practical standpoint, there is little difference between delay and prevention of 
a disease such as type 2 diabetes with variable and late onset. If an intervention could delay the onset of diabetes 
long enough such that a person ultimately dies without developing the disease, delay would be equivalent to 
prevention. Unfortunately, neither of the DPP interventions (4) was totally effective, i.e., neither reduced the 
diabetes incidence rate to zero. Thus they produced only partial delay or prevention. Even partial effectiveness in 
this regard, however, is beneficial and is cause for optimism that more effective interventions can be developed. 
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